Temisartan/Amlodipine+Rosuvastatin + YHP1604
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension, Hyperlipidemia
Trial Timeline
Apr 21, 2017 → May 26, 2017
NCT ID
NCT03116516About Temisartan/Amlodipine+Rosuvastatin + YHP1604
Temisartan/Amlodipine+Rosuvastatin + YHP1604 is a phase 1 stage product being developed by Yuhan for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03116516. Target conditions include Hypertension, Hyperlipidemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03116516 | Phase 1 | Completed |
Competing Products
20 competing products in Hypertension
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85